Poster 16

Improvements in itch and sleep disturbance are maintained up to week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)

Authors: Jonathan I Silverberg, Andreas Wollenberg, Franz J Legat, Vivian T Laquer, Liliana Ulianov, Soo Yeon Cheong, Anna Ryzhkova, Christophe Piketty

<PREVIOUS POSTER | NEXT POSTER>

Poster 16